NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

Rhea-AI Summary

NeurAxis (NYSE American: NRXS) will release summarized financial results for its second quarter ended June 30, 2026, before market open on Tuesday, August 11, 2026. The company will host a conference call the same day at 9:00 a.m. ET to review the results, with live phone and webcast access plus a replay option.

Market Context

2.58% was the average move across two prior earnings-date notices. The current announcement only sch...

Analysis

2.58% was the average move across two prior earnings-date notices. The current announcement only schedules second-quarter results; the active S-3 is a resale registration, while low short positioning remained a separate contextual risk.

Key Figures

Reporting period: Q2 2026 Results date: August 11, 2026 Conference call time: 9:00 am ET

3 metrics

Reporting period Q2 2026 Period ended June 30, 2026

Results date August 11, 2026 Results scheduled before market open

Conference call time 9:00 am ET August 11, 2026

Previous Earnings date Reports

2 past events · Latest: May 05 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Q1 earnings date	Neutral	+4.7%	Scheduled first-quarter results and conference call for May 12
Mar 12	FY earnings date	Neutral	+0.5%	Scheduled fourth-quarter and full-year results for March 19

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two prior earnings-date notices were followed by positive 24-hour price reactions despite being scheduling announcements.

Key Terms

neuromodulation

1 terms

neuromodulation medical

"a medical technology company commercializing neuromodulation therapies"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.

Conference Call Details

Date and Time: Tuesday, August 11, 2026, at 9:00am ET

Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060
Webcast: https://app.webinar.net/E5zrP9X7wLY

Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 8443629
Webcast: https://app.webinar.net/E5zrP9X7wLY

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.

For more information, please visit http://neuraxis.com.

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

FAQ

When will NeurAxis (NRXS) report its Q2 2026 financial results?

NeurAxis will report summarized Q2 2026 financial results on Tuesday, August 11, 2026, before market open. According to NeurAxis, the announcement covers the quarter ended June 30, 2026, and will be followed by a results conference call.

What time is the NeurAxis (NRXS) Q2 2026 earnings conference call on August 11, 2026?

The NeurAxis Q2 2026 conference call is scheduled for 9:00 a.m. ET on August 11, 2026. According to NeurAxis, the call will review summarized financial results for the quarter ended June 30, 2026.

How can investors join the NeurAxis (NRXS) Q2 2026 earnings call by phone?

Investors can join by dialing 1-877-270-2148 (U.S. and Canada toll-free) or 1-412-317-6060 internationally. According to NeurAxis, these numbers provide direct access to the August 11, 2026, 9:00 a.m. ET results call.

Is there a webcast for the NeurAxis (NRXS) Q2 2026 earnings and business update call?

Yes. NeurAxis will offer a live webcast at https://app.webinar.net/E5zrP9X7wLY for its Q2 2026 call. According to NeurAxis, the webcast will stream the August 11, 2026, 9:00 a.m. ET discussion.

How can I access the replay of the NeurAxis (NRXS) Q2 2026 earnings call?

A replay will be available via 1-855-669-9658 (U.S. and Canada) or 1-412-317-0088 internationally, using replay access code 8443629. According to NeurAxis, a replay webcast will also be available at the original webcast link.

What period does NeurAxis (NRXS) Q2 2026 financial report cover?

The Q2 2026 financial report will cover the period ended June 30, 2026. According to NeurAxis, summarized financial results for this quarter will be released on August 11, 2026, before market open, followed by a conference call.